Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101241 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 RCT Study of CX-8998 for Essential Tremor
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT03101241 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 95 participants.
The verdict
NCT03101241, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of participants on primidone at baseline who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening results from all patients meeting the eligibility requirements will be further assessed by the sponsor medical personnel for final approval of suitability for inclusion in the study. Randomized participants will enter a 4 week double-blind dose-titration treatment period, followed by a 1 week safety follow-up period following the last dose of study medication, and a scheduled follow-up safety telephone call one week later.
Interventions
- DRUG Placebo
- DRUG CX-8998
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2017-08-29 |
| Est. Completion | 2018-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03101241
The ClinicalTrials.gov registry entry for NCT03101241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03101241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03101241 about?
NCT03101241 is a clinical study titled "A Phase 2 RCT Study of CX-8998 for Essential Tremor". This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of participants on primidone at baseline who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening results from all patient...
What is the current status of trial NCT03101241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2017-08-29. Estimated completion is 2018-07-16.
What interventions are being tested in trial NCT03101241?
The interventions under investigation include: Placebo (DRUG), CX-8998 (DRUG).
Who is sponsoring clinical trial NCT03101241?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.